Efficacy and safety of saroglitazar on vascular function in patients with type 2 diabetes mellitus: A randomized, double blind, parallel arm, placebo controlled trial - STARDDOM

JIPMER Intramural Research Grant0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•Patients with type 2 diabetes mellitus diagnosed by American Diabetes Association (ADA) criteria within the past 3 months to 10 years, on stable dose of metformin with or without sulfonylureas, for at least past 2 months, with HbA1C of 7.5-9%

•1) Liver dysfunction (AST,ALT > 2 times the upper limit of normal)
•2) Renal dysfunction (GFR <60 ml/min/1.73 m2)
•3) Patient with concurrent illnesses like CAD(Coronary Artery Disease), CVA( cerebrovascular accidents), PVD(Peripheral Vascular Disease), CKD( Chronic Kidney Disease)other than hypertension
•4) Patients taking anti diabetic drugs other than metformin and sulfonylureas
•5) Pregnant women or lactating mothers; women in reproductive age group not practicing contraceptive measures.
•6) Patients who had participated in other trials in the past three months.
•7) Patients with active infections such as diabetic foot infection etc

发起方

JIPMER Intramural Research Grant